newsfilter
← Latest News
GlobeNewswire·

Liquidia Corporation Reports Second Quarter 2026 Financial Results

YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026Approximately 5,900 unique patient prescriptions and more